NUCLEAR DIAGNOSTIC PRODUCTS OF PHILADELPHIA, INC

NUCLEAR DIAGNOSTIC PRODUCTS OF PHILADELPHIA, INC specializes in the manufacturing of radiopharmaceuticals for diagnostic imaging, with a focused expertise in the production of targeted radiolabeled compounds used in nuclear medicine. The company’s core capabilities center on GMP-compliant radiopharmaceutical synthesis, isotopic labeling, and sterile formulation of agents such as ILLUCCIX and GA68, which are administered for positron emission tomography (PET) and other molecular imaging applications. Their technical proficiency includes radiolysis control, cold kit reconstitution, automated synthesis modules, and strict adherence to USP <825> standards for radiopharmaceutical handling. The firm demonstrates a specialized niche in producing short-lived, high-specific-activity agents requiring precise radiochemical purity and rapid distribution logistics, positioning them as a critical supplier in the diagnostic nuclear medicine supply chain. The company maintains a consistent and enduring relationship with the Department of Veterans Affairs, supplying FDA-approved radiopharmaceuticals to VA medical centers nationwide for oncology, cardiology, and neurology diagnostics. This recurring engagement reflects a trusted, mission-critical partnership built on reliable product delivery, regulatory compliance, and adherence to VA-specific procurement protocols for nuclear pharmacy services. Operating under NAICS 325412, the firm is deeply embedded in the pharmaceutical preparation manufacturing sector, with a vertical specialization in radiopharmaceuticals rather than traditional small-molecule or biologic drugs. This focus places them at the intersection of nuclear science, oncology diagnostics, and precision medicine, serving a high-regulation, low-volume, high-precision market segment. As a small business structured as a 2L entity based in Cherry Hill, New Jersey, the company operates without federal certifications such as 8(a), HUBZone, or SDVOSB. Its geographic footprint is centered in the Mid-Atlantic region, with a national supply footprint supporting federal healthcare delivery systems through specialized radiopharmaceutical manufacturing.